explore -WSS

explore

author：entertainment 2025-10-01 12:54:46 - browse：69

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Living with Fabry disease, a condition that causes chronic pain

Wikipedia

WSS

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Palantir health business leans on meeting customers’ needs

Living with Fabry disease, a condition that causes chronic pain

Bulgari apologizes to China for listing Taiwan as a country after online backlash

California’s proposed $25 per hour health care minimum wage

Bird flu researchers hone in on Finland’s mink farms

leisure time

explore

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

focus

Cancer drug shortages should be causing more outrage

Surge in Apellis stock fueled by confidence in safety of its eye drug

As demand for Covid shots wanes, Moderna seeks its next success

Study: Pain burden is higher in Black NFL players than white ones

Jerome Adams on the need for new antivirals for Covid

Megan Rapinoe shares emotional post following US Women's World Cup exit

At least 13 dead in Texas as scorching temps continue

Indictment alleges Trump's ex

Drug repurposing or repositioning? The language matters

What to know about OceanGate, the company behind the missing Titanic submersible

focus

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

California’s proposed $25 per hour health care minimum wage

A new study sees potential in DNA sequencing of infants

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Palantir health business leans on meeting customers’ needs

Timeline: How the deadly wildfires took over Maui day by day

knowledge

Wikipedia

focus

knowledge